Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
[39] Insulin secretion is typically associated with release of islet amyloid polypeptide (IAPP), also known as amylin, which has been hypothesized to predict the degree of β-cell dysfunction.
Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...
The candidate is a long-acting amylin analog for the treatment of obesity, and I am delighted to see that AbbVie did not just in-license another incretin therapy (GLP-1 or GLP-1/GIP agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback